(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 September 2014 (12.09.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/138449 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 39/395* (2006.01)
C07K 16/30 (2006.01) *A61P 35/00* (2006.01)
C07K 16/46 (2006.01)

(21) International Application Number:
PCT/US2014/021341

(22) International Filing Date:
6 March 2014 (06.03.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/773,764 6 March 2013 (06.03.2013) US
61/773,788 6 March 2013 (06.03.2013) US

(71) Applicants: **MERRIMACK PHARMACEUTICALS, INC.** [US/US]; One Kendall Square, Suite B7201, Cambridge, Massachusetts 02139 (US). **ADIMAB, LLC** [US/US]; 7 Lucent Drive, Lebanon, New Hampshire 03766 (US).

(72) Inventors: **HARMS, Brian**; 152 Walter Street, #1, Roslindale, Massachusetts 02131 (US). **KOHLI, Neeraj**; 39 Shepard Street, Apt. 17, Brighton, Massachusetts 02135 (US). **LUGOVSKOY, Alexey**; 24 Center Street, Woburn, Massachusetts 01801 (US). **GEDDIE, Melissa**; 69 Highland Road, #1, Somerville, Massachusetts 02144 (US). **KRAULAND, Eric Mark**; 7 Lucent Drive, Lebanon, New Hampshire 03766 (US). **ROACH, William George**; 7 Lucent Drive, Lebanon, New Hampshire 03766 (US). **SU, Stephen**; 1 Emerson Place, Apt. 10C, Boston, Massachusetts 02114 (US). **ABU-YOUSIF, Adnan**; 70 Lincoln St. Apt 412, Boston, Massachusetts 02111 (US).

(74) Agents: **PENNER, Steven J.** et al.; Lathrop & Gage LLP, 4845 Pearl East Circle, Suite 201, Boulder, Colorado 80301 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: ANTI-C-MET TANDEM FC BISPECIFIC ANTIBODIES

U-87 MG dose-response

Fig. 32



(57) Abstract: Provided herein are tandem Fcs and tandem Fc antibodies ("TFcAs"), e.g., tandem Fc bispecific antibodies ("TFcBAs"), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a TFc, which TFc comprises a first Fc region and a second Fc region, wherein the first and the second Fc regions are linked through a TFc linker to form a contiguous polypeptide and dimerize to form an Fc dimer. Exemplary TFcBAs bind to the cell surface receptors c-Met and EpCam and inhibit signal transduction through the cell surface receptor(s) for which the binding sites of the TFcBA are specific.

WO 2014/138449 A1

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*